DAFNA Capital Management’s Palvella Therapeutics PVLA Stock Holding History

DAFNA Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,348	Closed	-$977K	–	83
2025 Q2	$977K	Hold	43,348	–	–	0.27%	58
2025 Q1	$1.21M	Sell	43,348 -28,104	-39%	-$542K	0.34%	50
2024 Q4	$857K	Buy	+71,452	New	+$1.12M	0.22%	64
2017 Q2	–	Sell	-669	Closed	-$139K	–	79
2017 Q1	$139K	Sell	669 -2,123	-76%	-$376K	0.12%	67
2016 Q4	$314K	Hold	2,792	–	–	0.28%	57
2016 Q3	$408K	Hold	2,792	–	–	0.28%	59
2016 Q2	$360K	Buy	2,792 +2,164	+345%	+$332K	0.29%	66
2016 Q1	$95K	Buy	+628	New	+$88.3K	0.08%	83
2015 Q3	–	Sell	-1,563	Closed	-$344K	–	92
2015 Q2	$344K	Buy	+1,563	New	+$344K	0.29%	59

Other funds holding PVLA

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

DAFNA Capital Management's PVLA Position: Q3 2025 in Review

DAFNA Capital Management sold out of Palvella Therapeutics (PVLA) in Q3 2025, closing a stake of 43,348 shares — an estimated $977K sold.

DAFNA Capital Management first reported a position in PVLA in Q2 2015 and held it in 9 quarters. The position peaked at $1.21M in Q1 2025. 100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

DAFNA Capital Management reported no remaining Palvella Therapeutics position as of Q3 2025 after selling out during the quarter.
DAFNA Capital Management sold 43,348 Palvella Therapeutics shares in Q3 2025, an estimated $977K.
DAFNA Capital Management first reported a position in Palvella Therapeutics in Q2 2015 and held it in 9 quarters.
DAFNA Capital Management's Palvella Therapeutics position peaked at $1.21M in Q1 2025.
100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on DAFNA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.